Davies Peter Miles Winston 4

What Happened
Davies Peter Miles Winston, a director of Neuphoria Therapeutics, was granted 8,537 restricted stock units (RSUs) on January 20, 2026. The Form 4 records this as a derivative acquisition (transaction code A) at $0.00 per unit (total recorded value $0.00). This grant is part of the company’s Board of Directors annual remuneration.

Key Details

• Transaction date: 2026-01-20; Filing date: 2026-01-21 (filed next business day).
• Security: 8,537 RSUs (each RSU converts to one share upon vesting). Price reported: $0.00 per RSU.
• Shares owned after transaction: not specified in the provided filing data.
• Footnotes: F1—each RSU equals a contingent right to one share; F2—grant made under the Board’s annual remuneration policy; F3—RSUs vest only if the reporting person remains in continuous service through the earlier of the day before the next annual shareholder meeting (expected by Dec 15, 2026) or the effective date of a Change in Control.
• Transaction type: Award/Grant (A). No sale or open-market purchase occurred.

Context
RSU grants are compensation awards and are derivative until they vest and are settled in shares (or otherwise). They do not involve an immediate cash outlay by the insider and are generally less informative about an insider’s personal market view than open‑market purchases or sales. The vesting conditions here tie the award to continued service (or a change in control), so shares will only be issued if those conditions are met.